The Lancet Respiratory Medicine· Jessica Gates, Joanne E Kavanagh, Grainne d’Ancona, Jaideep Dhariwal, Alexandra M Nanzer, David J Jackson·· 2026-08-26AI 评分52
重度哮喘中识别尚未满足的残留需求
[Correspondence] Identifying the residual unmet need in severe asthma
AI 导读
该通讯指出过去十年获批的生物制剂显著改善了重度哮喘治疗前景,包括 anti-IgE、anti-IL5(mepolizumab)、anti-IL5R(benralizumab)、靶向 IL-4 受体(dupilumab)及 TSLP 抑制剂(tezepelumab)。
来源:The Lancet Respiratory Medicine · thelancet.com